on the X-ray inactivated CF1 MEFs in 100 mm dish and incubated with mESC growth medium: Knockout TM DMEM, 20 % Knockout serum replacement, 1% Glutamax, 1% Non-essential amino acids, 1% penicillin/streptomycin, 0.1 mM β-mercaptoethanol and 10 3 U/ml mLIF (Millipore). After 10 days, the riPSC colonies were picked up for expansion on MEF feeder cells in mESC growth medium, and treated with MEK inhibitor PD0325901 (Stemgent, 0.5 µM), ALK5 inhibitor A-83-01 (Tocris Bioscience, 0.5 µM), and GSK3β inhibitor CHIR99021 (Stemgent, 3 µM). Human fibroblasts IMR90 (ATCC No. CCL-186) were cultured and transduced by pSin-EF2-Puro-based lentiviruses for human Oct4, Sox2, Nanog and Lin28 (Addgene) as described (Yu et al., 2007) . 24 hours later, 1×10 5 transduced IMR-90 cells were seeded on the X-ray inactivated CF1 MEF feeder cells in a 100 mm dish. 24 hours later, the media was changed to mESC medium supplemented with 10 3 U/ml hLIF (Millipore). After three weeks, the hiPSC colonies were observed and picked up at the fourth week post-infection for expansion on feeder cells in the same medium containing MEK inhibitor PD0325901 (0.5 µM), ALK5 inhibitor A-83-01 (0.25 µM), and GSK3β inhibitor CHIR99021 (3 µM). All cell culture products were from Invitrogen/Gibco BRL except where mentioned. Cytochemistry and immunofluorescence assay: Alkaline Phosphatase staining was performed according to the manufacturer's protocol using the Alkaline Phosphatase Detection Kit (Millipore). For immunofluorescence assay, cells were fixed in 4% paraformaldehyde for 10 minutes and washed three times with PBS containing 0.1% Triton X-100 (Sigma-Aldrich). The fixed cells were then incubated in blocking buffer, 0.1% Triton X-100 and 10% normal donkey serum (Jackson ImmunoResearch Laboratories Inc) in PBS (Invitrogen/Gibco BRL), for 30 min at room temperature (RT). The cells were then incubated with primary antibody overnight at 4°C in blocking buffer. The day after, cells were washed with PBS and incubated with secondary antibody in PBS containing 0.1% Triton X-100 for one hour at RT. Mouse anti-Oct4 antibody (1:250) (Santa Cruz Biotechnology), rabbit anti-Sox2 antibody (1:2000) (Chemicon), mouse anti-SSEA1 antibody (1:250) (Santa Cruz Biotechnology), rabbit anti-Nanog antibody (1:500) (Abcam), rat anti-SSEA3 antibody (1:1000) (Chemicon), mouse anti-SSEA4 antibody (1:1000) (Chemicon), mouse anti-TRA-1-81 antibody (1:1000) (Chemicon), rabbit anti-Pdx1 (1:1500), a gift from Dr. C. Wright (Vanderbilt University, TN), mouse anti-βIII-Tubulin (Tuj1) antibody (1:1000) (Covance Research Products), rabbit anti-albumin antibody (1:1000) (DAKO) were used as primary antibodies. Secondary antibodies were Alexa Fluor 486/555 donkey anti-mouse, anti-rat, anti-goat or anti-rabbit IgG (1:500) (Invitrogen). Nuclei were visualized by DAPI (Sigma-Aldrich) staining. Images were captured using a Nikon Eclipse TE2000-U microscope. Blastocyst Injection: The blastocysts were recovered from the uterus of Brown-Norway (BN) females at 4.5 days post coitum. The blastocysts were placed in a drop of HEPES under mineral oil. 8~15 riPSCs (clonal line 1) were injected into the blastocyst cavity using a microinjection pipette. After injection, blastocysts were transferred to pseudo-pregnant recipient females. All animal procedures were in accordance with the guidelines of the National Institute of Health.
Differentiation of iPSCs in vitro:
The in vitro differentiation of riPSCs or hiPSCs was carried out by the standard embryoid body differentiation methods. The riPSCs or hiPSCs were dissociated by 0.05 % Trypsin-EDTA and cultured in ultra-low attachment 100-mm dish in DMEM medium supplemented with 10% FBS to form embryoid body (EBs). The medium was changed every another day. One week later, the EBs were harvested and transferred into Matrigel-coated 6-well plate in DMEM medium with 10% FBS. Three to seven day later, the cells were fixed for immunocytochemistry analysis. All cell culture products were from Invitrogen/Gibco BRL except where mentioned. RT-PCR analysis: RNA was extracted from riPSCs and hiPSCs using the RNeasy Plus Mini Kit in combination with QIAshredder (Qiagene). Reverse transcription was performed with 1µg RNA using iScript TM cDNA Synthesis Kit (BioRad). Amplification of specific genes was done using primers showed in Table S1 . The PCR conditions were 95°C for 5 minutes, 94°C for 30 seconds, annealing temperature for 30 seconds, and 72°C for 30 seconds, 25~35 cycles, and then 72°C for 10 minutes. For Oct4 promoter methylation study using bisulfite-sequencing, DNAs from WB-F344 cells, riPSCs, IMR90, and hiPSCs were isolated using the Non Organic DNA Isolation Kit (Millipore). The DNAs were then treated with the EZ DNA Methylation-Gold Kit (Zymo Research Corp., Orange, CA). The treated DNAs were then used as templates to amplify sequences of interest. Primers used for Oct4 promoter fragment amplification were showed in Table S1 . The resulting fragments were cloned using the TOPO TA Cloning Kit for sequencing (Invitrogen) and sequenced. Teratoma Formation: The serially passaged riPSCs or hiPSCs were harvested by using 0.05 % Trypsin-EDTA. Three to five million cells were injected under the kidney capsule of SCID mice (n=3). After 4-5 weeks, all mice developed teratomas, which were removed and then histologically analyzed. Figure S1 . The effects of different small molecule combinations on maintaining the pluripotency of riPSCs in culture. riPSCs were trypsized into single cells and seeded into 6-well plate at the density of 10 3 cells per well and treated with different inhibitor combinations. Five days latter, ALP staining was performed to visualize the riPSC colonies (A). The ALP positive colonies for each condition were counted from ten random 40× visual fields and the relative colony number was summarized in (B). 
